In 87 women with untreated advanced triple-negative breast cancer (phase Ib/II BEGONIA), grade 3/4 adverse events (primary safety outcome) hit 43.5% with durvalumab plus paclitaxel, 80.6% adding capivasertib and 24.2% adding oleclumab; neither addition added substantial benefit.
RCTn = 87
Schmid et al. Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer